Eli Lilly and Company (NYSE:LLY) Trading Down 2.7% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price traded down 2.7% during trading on Monday . The company traded as low as $1,144.43 and last traded at $1,146.90. Approximately 2,632,708 shares changed hands during trading, a decline of 17% from the average daily volume of 3,177,944 shares. The stock had previously closed at $1,179.11.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts continue to point to Eli Lilly’s leadership in the GLP-1 market, expanding pipeline, and strong growth outlook as key support for the stock. Top Research Reports for Eli Lilly, Costco & Morgan Stanley
• Positive Sentiment: Wall Street reaction suggests investors are still favoring Lilly over Novo Nordisk in the obesity-drug race, implying confidence in Lilly’s competitive position despite the lawsuit. The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side
• Neutral Sentiment: Lilly confirmed it will report second-quarter 2026 results on August 5, keeping attention on upcoming earnings and guidance rather than just the legal dispute. Lilly confirms date and conference call for second-quarter 2026 financial results announcement
• Neutral Sentiment: Pre-earnings coverage says analysts expect double-digit earnings growth, which supports the stock but is already largely anticipated by investors. What You Need to Know Ahead of Eli Lilly’s Earnings Release
• Negative Sentiment: Novo Nordisk’s lawsuit raises legal and reputational risk for Eli Lilly’s obesity and diabetes marketing, which could weigh on sentiment if the case escalates or forces changes to ad campaigns. Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Guggenheim raised their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Citigroup increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Finally, Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company Trading Down 1.0%

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.10 trillion, a price-to-earnings ratio of 41.33, a P/E/G ratio of 1.44 and a beta of 0.51. The company has a fifty day simple moving average of $1,126.19 and a 200-day simple moving average of $1,037.68.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently made changes to their positions in the business. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $30,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares in the last quarter. Finally, Dorato Capital Management bought a new position in Eli Lilly and Company during the 4th quarter valued at about $36,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.